Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.
BRAF V600E mutation
cMET exon 14 skipping mutation
first-line treatment
non-small-cell lung cancer
real-world data
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
15
07
2023
revised:
12
08
2023
accepted:
15
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (
Identifiants
pubmed: 37629023
pii: ijms241612840
doi: 10.3390/ijms241612840
pmc: PMC10454089
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
BRAF protein, human
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Oncol Rep. 2021 Nov 4;23(12):138
pubmed: 34735635
Cancer Treat Rev. 2019 May;75:39-51
pubmed: 30954906
J Thorac Oncol. 2023 Apr;18(4):419-435
pubmed: 36441095
Transl Lung Cancer Res. 2021 Mar;10(3):1536-1556
pubmed: 33889528
Ann Transl Med. 2018 Apr;6(8):142
pubmed: 29862231
Front Oncol. 2022 Mar 31;12:863043
pubmed: 35433454
Transl Lung Cancer Res. 2017 Oct;6(5):560-569
pubmed: 29114472
Neoplasia. 2009 Dec;11(12):1292-300
pubmed: 20019837
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Lung Cancer. 2020 Dec;150:21-25
pubmed: 33045465
Biomedicines. 2021 May 11;9(5):
pubmed: 34064757
J Thorac Oncol. 2015 Oct;10(10):1451-7
pubmed: 26200454
Onco Targets Ther. 2020 Mar 25;13:2491-2510
pubmed: 32273721
World J Clin Oncol. 2021 Apr 24;12(4):217-237
pubmed: 33959476
Mol Genet Genomic Med. 2020 Sep;8(9):e1398
pubmed: 32657049
Int J Mol Sci. 2023 Mar 21;24(6):
pubmed: 36983011
Front Oncol. 2022 Oct 27;12:1013299
pubmed: 36387098
J Thorac Oncol. 2020 Apr;15(4):628-636
pubmed: 31945494
Curr Opin Oncol. 2018 Sep;30(5):345-351
pubmed: 29994900
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-23
pubmed: 33979196
Curr Oncol. 2018 Oct;25(5):e398-e402
pubmed: 30464690
Drugs. 2021 Sep;81(14):1665-1670
pubmed: 34455538
J Thorac Oncol. 2019 Mar;14(3):e57-e59
pubmed: 30782386
Expert Opin Biol Ther. 2019 Mar;19(3):225-232
pubmed: 30657338
Cancers (Basel). 2021 Aug 16;13(16):
pubmed: 34439273
Clin Transl Oncol. 2023 Jan;25(1):10-20
pubmed: 35729451
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Sci. 2021 Apr;112(4):1534-1544
pubmed: 33462883
J Clin Med. 2021 Nov 29;10(23):
pubmed: 34884316
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Future Oncol. 2013 May;9(5):699-711
pubmed: 23647298
Oncologist. 2022 Apr 21;:
pubmed: 35445725
Crit Rev Oncol Hematol. 2020 Aug;152:103008
pubmed: 32485528
Lancet Respir Med. 2021 Oct;9(10):1154-1164
pubmed: 34166627
Ther Adv Med Oncol. 2022 Jun 13;14:17588359221103206
pubmed: 35720834
Lung Cancer (Auckl). 2022 May 13;13:33-45
pubmed: 35592355
Oncology. 2022;100(9):467-474
pubmed: 35679833
Cancers (Basel). 2022 Oct 05;14(19):
pubmed: 36230797
Ann Oncol. 2019 Jul 1;30(7):1134-1142
pubmed: 30918950
J Thorac Oncol. 2022 Jan;17(1):103-115
pubmed: 34455067
ESMO Open. 2022 Apr;7(2):100449
pubmed: 35334419
J Clin Transl Res. 2021 Jan 20;7(1):1-21
pubmed: 34104805
J Natl Compr Canc Netw. 2022 May;20(5):497-530
pubmed: 35545176
AJNR Am J Neuroradiol. 2020 May;41(5):738-750
pubmed: 32217548
Future Oncol. 2023 Jan;19(3):217-228
pubmed: 36749292
Front Oncol. 2021 Jun 10;11:634920
pubmed: 34178624
Annu Rev Pathol. 2011;6:49-69
pubmed: 20887192
J Thorac Oncol. 2021 Jul;16(7):1086-1098
pubmed: 33845212
J Hematol Oncol. 2021 Aug 23;14(1):129
pubmed: 34425853
Ther Adv Med Oncol. 2021 Feb 15;13:1758835921992976
pubmed: 33643443
Transl Lung Cancer Res. 2021 Jun;10(6):2890-2916
pubmed: 34295687
Clin Cancer Res. 2022 Mar 15;28(6):1117-1126
pubmed: 34789481
Cancer Med. 2023 Feb;12(3):2666-2676
pubmed: 36052772
Nat Med. 2020 Jan;26(1):47-51
pubmed: 31932802
Expert Rev Anticancer Ther. 2018 Nov;18(11):1063-1068
pubmed: 30198802
J Thorac Oncol. 2018 Aug;13(8):1128-1137
pubmed: 29723688
Eur J Cancer. 2021 May;149:211-221
pubmed: 33872981
Front Oncol. 2022 Jul 13;12:882940
pubmed: 35912223
Br J Cancer. 2022 Apr;126(6):889-898
pubmed: 34963703
Curr Treat Options Oncol. 2020 Jul 27;21(8):69
pubmed: 32720019
J Adv Pract Oncol. 2022 Jul;13(5):539-544
pubmed: 35910499
Clin Cancer Res. 2013 Aug 15;19(16):4532-40
pubmed: 23833300
Signal Transduct Target Ther. 2021 May 31;6(1):201
pubmed: 34054126
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472
pubmed: 31805526